TY - JOUR
T1 - DAT polymorphism and diverse clinical manifestations in methamphetamine abusers
AU - Liu, Hsing Cheng
AU - Lin, Shih Ku
AU - Liu, Shih Kai
AU - Chen, Su Lien
AU - Hu, Chaur Jong
AU - Chang, Jan Gowth
AU - Leu, Sy Jye
PY - 2004/3
Y1 - 2004/3
N2 - The clinical outcome for methamphetamine (MAP) abusers is variable. MAP exerts its biological activity through rapid conversion to amphetamine (AP) and MAP itself. The dopamine transporter (DAT) is the main modulator of MAP/ AP-induced dopamine release and dopamine neurotoxicity, and is also the major regulator of dopamine level in the brain. We tested for an association between a DAT-gene polymorphism and clinical variations in MAP abusers. A total of 146 MAP abusers were enrolled in the study and classified into three clinically distinct groups: MAP dependence (n=30), MAP psychosis (n=88) and chronic MAP psychosis (n=28). Patients with schizophrenic (n=79) and healthy controls (n=72) were also recruited for the study. The 40 base pair variable number tandem repeat polymorphism in the 3′-untranslated region of the DAT was the focus of the investigation. The subjects were all Chinese residents of Taiwan. The respective allelic frequencies for DAT repeats 11, 10 and 9 were 0.067, 0.833 and 0.083 for the MAP-dependence group, 0.006, 0.864 and 0.119 for the MAP psychosis group, 0.018, 0.893 and 0.089 for the chronic MAP psychosis group, 0.019, 0.911 and 0.07 for the schizophrenic controls, and 0.021, 0.889 and 0.083 for the healthy controls. No significant associations were demonstrated between this DAT polymorphism in genotype and allele frequency and the clinical outcome of MAP abusers. The biological relevance of the variable number tandem repeat polymorphism in the 3′-untranslated region of DAT in MAP abusers was not demonstrated in this study.
AB - The clinical outcome for methamphetamine (MAP) abusers is variable. MAP exerts its biological activity through rapid conversion to amphetamine (AP) and MAP itself. The dopamine transporter (DAT) is the main modulator of MAP/ AP-induced dopamine release and dopamine neurotoxicity, and is also the major regulator of dopamine level in the brain. We tested for an association between a DAT-gene polymorphism and clinical variations in MAP abusers. A total of 146 MAP abusers were enrolled in the study and classified into three clinically distinct groups: MAP dependence (n=30), MAP psychosis (n=88) and chronic MAP psychosis (n=28). Patients with schizophrenic (n=79) and healthy controls (n=72) were also recruited for the study. The 40 base pair variable number tandem repeat polymorphism in the 3′-untranslated region of the DAT was the focus of the investigation. The subjects were all Chinese residents of Taiwan. The respective allelic frequencies for DAT repeats 11, 10 and 9 were 0.067, 0.833 and 0.083 for the MAP-dependence group, 0.006, 0.864 and 0.119 for the MAP psychosis group, 0.018, 0.893 and 0.089 for the chronic MAP psychosis group, 0.019, 0.911 and 0.07 for the schizophrenic controls, and 0.021, 0.889 and 0.083 for the healthy controls. No significant associations were demonstrated between this DAT polymorphism in genotype and allele frequency and the clinical outcome of MAP abusers. The biological relevance of the variable number tandem repeat polymorphism in the 3′-untranslated region of DAT in MAP abusers was not demonstrated in this study.
KW - Dopamine
KW - Dopamine transporter
KW - Methamphetamine
KW - Schizophrenia
KW - Variable number tandem repeat polymorphism
UR - http://www.scopus.com/inward/record.url?scp=1642327100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642327100&partnerID=8YFLogxK
U2 - 10.1097/00041444-200403000-00005
DO - 10.1097/00041444-200403000-00005
M3 - Article
C2 - 15091313
AN - SCOPUS:1642327100
VL - 14
SP - 33
EP - 37
JO - Psychiatric Genetics
JF - Psychiatric Genetics
SN - 0955-8829
IS - 1
ER -